[시장보고서]만성 완전폐색(CTO) 시장 규모와 예측(2021-2031년), 세계 및 지역 점유율, 동향, 성장 기회 분석 : 기기별, 최종 사용자별, 지역별

만성 완전폐색(CTO) 시장 규모와 예측(2021-2031년), 세계 및 지역 점유율, 동향, 성장 기회 분석 : 기기별, 최종 사용자별, 지역별

Chronic Total Occlusion Market Size and Forecast 2021-2031, Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage:By Equipment, End User, and Geography

상품코드 : 1858581 해당 상품은 즉시 배송 가능합니다

리서치사 : The Insight Partners

발행일 : 2025년 09월

페이지 정보 : 영문 195 Pages

라이선스 & 가격 (부가세 별도)

US $ 4,450

￦ 6,602,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다.

US $ 6,450

￦ 9,569,000

PDF (Site License)

PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 8,450

￦ 12,537,000

PDF (Enterprise License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

샘플 요청 목록에 추가

만성 완전폐색(CTO) 시장은 2024년 24억 4,000만 달러로 평가되었고, 2031년에는 42억 2,000만 달러에 이를 것으로 예측되며, 2025-2031년 CAGR은 8.2%로 예측됩니다. 고령화 인구 증가와 심혈관 질환 유병률 상승이 만성 완전폐색 시장 규모 확대에 기여하고 있습니다. 그러나 폐색 장치의 높은 비용은 만성 완전폐색 시장 성장을 저해하는 요인입니다. 또한 향후 몇 년간 CTO 장치의 기술 발전이 새로운 만성 완전폐색 시장 동향을 가져올 것으로 예상됩니다.

수익 측면에서 북미는 2024년 시장을 주도했습니다. 예측 기간 동안 글로벌 시장을 주도할 것으로 추정됩니다. 미국은 세계 최대 만성 완전폐색 시장입니다.

미국 만성 완전폐색 시장은 고령 인구에서 심혈관 질환(특히 관상동맥질환, CAD) 발생률이 증가함에 따라 성장하고 있습니다. 미국심장협회(AHA)의 2023년 심장병 및 뇌졸중 통계 업데이트에 따르면, 미국 내 약 1,820만 명의 성인이 CAD를 앓고 있는 것으로 나타났습니다. 경피적 관상동맥 중재술(PCI)을 포함한 최소 침습적 방법의 채택과 정교한 CTO 전용 기기의 개발이 시장 성장의 주요 동력입니다. 메드트로닉, 보스턴 사이언티픽, 애보트 래버러토리스, 필립스 헬스케어 등 글로벌 선도 기업들은 CTO 시술을 위한 혁신적인 기기와 기술로 미국 시장을 주도하고 있습니다. 강력한 의료 인프라, 보험급여 정책, 환자 결과 개선에 대한 강조가 시장 성장을 촉진합니다. 전문 센터와 숙련된 심장전문의의 증가 역시 CTO 시술 적용에 유리하게 작용합니다. 직업 고용 및 임금 통계국에 따르면, 2023년 기준 미국 내 고용된 심장전문의는 1만 5,190명입니다. 또한 심혈관 건강에 대한 인식 제고와 CTO의 조기 발견은 이러한 중재적 시술에 대한 수요를 촉진합니다.

만성 완전폐색 시장 분석

미래 시장 기회를 창출하기 위한 시장 참여자들의 전략적 이니셔티브

CTO 시장에서 활동하는 기업들은 제품 승인, 협력, 자금 조달, 계약 체결, 신제품 출시 등 전략적 발전에 지속적으로 주력하고 있습니다. 이는 매출 증대, 지리적 범위 확대, 기존 고객 기반 이상의 수요 충족 역량 강화에 기여합니다. CTO 시장에서 주요 기업들이 추진한 몇 가지 전략적 이니셔티브는 다음과 같습니다.

2022년 2월, Teleflex Incorporated는 미국 식품의약국(FDA)이 회사의 특수 카테터 및 관상동맥 가이드와이어에 대해 특히 만성 완전폐색 경피적 관상동맥 인터벤션(CTO PCI)의 사용에 적응 확대를 인정했다고 발표했습니다.
2024년 6월 MicroPort RotaPace의 혈관 내 압전 가이드와이어 시스템은 혁신적인 의료기기에 대한 특별 심사 절차에 참여하기 위해 NMPA의 승인을 받았습니다. 이 시스템은 복단 대학 나카야마 병원의 갈순 학장이 이끄는 팀에 의해 공동 개발되었습니다.
2024년 2월, BIOTRONIK는 Micro Rx 카테터를 발표했습니다. Micro Rx 카테터는 PCI에서 가이드와이어 지지를 쉽게 강화하기 위해 개발된 새로운 고속 교환 마이크로카테터입니다. Micro Rx 카테터는 BIOTRONIK가 미국 시장에 투입한 네 번째 IMDS 제품으로 NHancer Rx, TrapIT, ReCross 카테터를 포함한 강력한 장비 포트폴리오에 기여하고 있습니다.
2022년 10월, FDA 승인 마이크로카테터 NovaCross 라인(무하 치료용 NovaCross BTK, 만성 완전폐색 치료용 NovaCross Xtreme, 만성 완전폐색 치료용 NovaCross CTO)는 Microbot Medical Inc.에서 Nitiloop Ltd.에서 구입한 자산 중 하나입니다. NovaCross 장치는 경피관 관상 동맥 성형술과 스텐트 인터벤션 전에 만성 완전폐색을 포함한 협착 병변 앞에 기존 가이드와이어와 스티어러블 가이드와이어를 쉽게 배치 할 수 있도록 설계되었습니다.
2022년 4월, FDA는 교통 과학의 XO 크로스 지원 카테터 플랫폼을 관상 동맥용으로 승인했습니다. 이 플랫폼은 말초 동맥이나 관상 동맥에 접근할 때 와이어의 교환을 용이하게 하고, 가이드와이어를 유도 및 유지하고, 진단용 조영제나 생리 식염수를 투여하기 위한 도관으로서 기능하는 것을 목적으로 하고 있습니다.
2022년 2월, FDA는 텔레플렉스 인코포레이티드의 전용 카테터 및 관상동맥 가이드와이어에 대해 경피적 관상동맥 인터벤션(PCI) 시 만성 완전폐색(CTO)을 횡단할 때 사용하는 적응증을 추가로 승인했습니다.
2023년 9월, 아빙거는 차세대 이미지 가이드 아래 CTO 횡단 시스템 'Tigereye ST'의 본격적인 상업 개시를 발표했습니다. 본격적인 상업 판매가 시작됨에 따라 현재 Tigereye ST 장치를 주문하는 고객과 향후 주문을 계획하는 고객은 모두 Tigereye ST 장치를 주문할 수 있습니다.

따라서 향후 몇 년간 제품 출시, 승인 및 협력은 만성 완전 폐색(CTO) 시장의 성장에 풍부한 기회를 창출할 것으로 예상됩니다.

만성 완전폐색 시장 보고서 부문 분석

만성 완전폐색 시장 분석에 기여한 주요 부문은 장비 및 최종 사용자입니다.

장비별로 만성 완전폐색 시장은 가이드와이어, 마이크로카테터, 크로스 장치, 리엔트리 장치 등으로 구분됩니다. 2024년에는 가이드와이어 부문이 시장의 최대 점유율을 차지했습니다.
최종 사용자별로 만성 완전폐색 시장은 병원, 외래 의료 센터 등으로 분류됩니다. 2024년에는 병원 부문이 시장을 독점했습니다.

만성 완전폐색 시장 : 경쟁 구도와 주요 발전

Asahi Intecc Co Ltd, Cordis Corp, Integer Holdings Corp, Boston Scientific Corp, Becton Dickinson and Co, SoundBite Medical Solutions, Medtronic Plc, Terumo Corp, Abbott, Koninklijke Philips NV 등이 만성 완전폐색 시장에서 사업을 전개하는 주요 기업입니다.

미국 인구조사국(US Census Bureau), 세계보건기구(WHO), 영국 심장 재단(British Heart Foundation), 프랑스 국립 인구 통계 연구소(French National Institute for Demographic Studies), 국가 통계 연구소(NIS), 국립 의학 도서관(National Library of Medicine), 국가 범죄 기록국(NCRB), 국립 생물공학 정보 센터(National Center for Biotechnology Information) 등이 만성 완전 폐색 시장 보고서 작성 시 참고한 1차 및 2차 자료 출처입니다.

만성 완전폐색 시장 : 주요 시장 역학
시장 성장 촉진요인
- 고령화 인구 증가
- 심혈관 질환의 유병률의 상승
시장 성장 억제요인
- 폐색 장치의 고비용
시장 기회
- 시장기업의 전략적 이니셔티브
향후의 동향
- CTO 장치의 기술 발전
성장 촉진요인과 억제요인의 영향

제6장 만성 완전폐색 시장 : 세계 시장 분석

만성 완전폐색 시장의 수익과 예측(2021-2031년)
만성 완전폐색 시장 예측과 분석
주요 기업의 시장 포지셔닝

제7장 만성 완전폐색 시장 수량 및 수익 분석 : 기기별

가이드와이어
마이크로카테터
크로스 장치
리엔트리 장치
기타

제8장 만성 완전폐색 시장 수익 분석 : 최종 사용자별

병원
외래 의료 센터
기타

제9장 만성 완전폐색 시장 분석 : 지역별

북미
- 미국
- 캐나다
- 멕시코
유럽
- 독일
- 영국
- 프랑스
- 스페인
- 이탈리아
- 기타 유럽
아시아태평양
- 중국
- 일본
- 인도
- 호주
- 한국
- 기타 아시아태평양
중동 및 아프리카
- 사우디아라비아
- 남아프리카
- 아랍에미리트(UAE)
- 기타 중동 및 아프리카
중남미
- 브라질
- 아르헨티나
- 기타 중남미

제10장 COVID-19 팬데믹이 세계의 만성 완전폐색 시장에 미치는 영향

북미
유럽
아시아태평양
중동 및 아프리카
중남미

제11장 만성 완전폐색 시장 : 업계 정세

만성 완전폐색 시장의 성장 전략
유기적 성장 전략
무기적 성장 전략

제12장 기업 프로파일

Asahi Intecc Co Ltd
Cordis Corp
Integer Holdings Corp
Boston Scientific Corp
Koninklijke Philips NV
Becton Dickinson and Co
Sound Bite Medical Solutions
Medtronic Plc
Terumo Corp
Abbott Laboratories

제13장 부록

HBR

영문 목차

영문목차

The Chronic Total Occlusion market is anticipated to grow from US$ 2.44 billion in 2024 and is projected to reach US$ 4.22 billion by 2031; it is expected to register a CAGR of 8.2% during 2025-2031. increasing aging population and the rising prevalence of cardiovascular diseases are contributing to the growing chronic total occlusion market size. However, the high cost of occlusion devices hampers the chronic total occlusion market growth. Further, technological advancements in CTO devices is expected to bring in new chronic total occlusion market trends in the coming years.

In terms of revenue, North America dominated the market in 2024. It is estimated to dominate the global market during the forecast period. The US is the largest market for chronic total occlusion in the world.

The US chronic total occlusion market is growing with the rising incidence of CVD, especially Coronary Artery Disease (CAD), in the aging population. The American Heart Association's (AHA) 2023 Heart Disease and Stroke Statistics Update mentions that approximately 18.2 million adults in the country had CAD. The adoption of minimally invasive methods, including percutaneous coronary intervention (PCI), and the development of sophisticated CTO-specific devices are the major driving forces for market growth. Global leaders such as Medtronic, Boston Scientific, Abbott Laboratories, and Philips Healthcare dominate the US market with their innovative devices and technologies for CTO procedures. The strong healthcare infrastructure, reimbursement policies, and emphasis on enhancing patient outcomes fuel market growth. The growing number of specialized centers and well-trained cardiologists favor the application of CTO procedures. As per the Division of Occupational Employment and Wage Statistics, there were 15,190 employed cardiologists in the US as of 2023. In addition, growing consciousness about cardiovascular health and detection of CTO at an early stage fuel the demand for these interventions.

Chronic Total Occlusion Market Analysis

Strategic Initiatives by Market Players to Provide Market Opportunities in Future

Companies operating in the CTO market constantly focus on strategic developments such as product approvals, collaborations, funding, agreements, and new product launches, which help them improve their sales, increase their geographic reach, and reinforce their capacities to cater to a greater than existing customer base. A few strategic initiatives by key players operating in the CTO market are mentioned below.

In February 2022, Teleflex Incorporated announced that the U.S. Food and Drug Administration (FDA) granted expanded indications for its specialty catheters and coronary guidewires, specifically for use in chronic total occlusion percutaneous coronary interventions (CTO PCI).
In June 2024, MicroPort RotaPace's Intravascular Piezoelectric Guidewire System gained NMPA approval for entry into the special review procedures for innovative medical devices. This system was co-developed by a team led by Academician Junbo Ge from Zhongshan Hospital, Fudan University.
In February 2024, BIOTRONIK introduced the Micro Rx catheter, a novel rapid exchange microcatheter developed to easily enhance guidewire support during PCI. The Micro Rx catheter is the fourth IMDS product that BIOTRONIK has introduced to the US market, contributing to a strong portfolio of devices, which includes the NHancer Rx, TrapIT, and ReCross catheters.
In October 2022, the FDA-approved NovaCross line of microcatheters (NovaCross BTK for below-the-knee treatment, NovaCross Xtreme for chronic total occlusion treatment, and NovaCross CTO for chronic total occlusion treatment) was among the assets that Microbot Medical Inc. purchased from Nitiloop Ltd. The NovaCross devices are designed to make it easier to implant conventional and steerable guidewires intraluminally beyond stenotic lesions, including chronic complete occlusions, prior to percutaneous transluminal coronary angioplasty or stent intervention.
In April 2022, the FDA approved Transit Scientific's XO Cross Support Catheter Platform for coronary usage. The platform is intended to facilitate wire exchanges, guide and maintain a guidewire during access to the peripheral or coronary arteries, and serve as a conduit for the administration of diagnostic contrast agents or saline solutions.
In February 2022, the FDA approved an additional indication for Teleflex Incorporated's specialized catheters and coronary guidewires to be used in crossing chronic complete occlusion (CTO) during percutaneous coronary intervention (PCI).
In September 2023, Avinger, Inc. announced the full commercial launch of its Tigereye ST next-generation image-guided CTO crossing system. With the initiation of a full commercial launch, all current and prospective accounts can now order the Tigereye ST device.

Therefore, product launches, approvals, and collaborations are expected to create ample opportunities for the growth of the chronic complete occlusion (CTO) market in the coming years.

Chronic Total Occlusion Market Report Segmentation Analysis

Key segments that contributed to the derivation of the chronic total occlusion market analysis are equipment and end user.

Based on equipment, the chronic total occlusion market is segmented into guide wires, micro catheters, crossing devices, re-entry devices, and others. The guide wires segment held the largest share of the market in 2024.
In terms of end user, the chronic total occlusion market is categorized into hospitals, ambulatory care centers, and others. The hospitals segment dominated the market in 2024.

Chronic Total Occlusion Market: Competitive Landscape and Key Developments

Asahi Intecc Co Ltd, Cordis Corp, Integer Holdings Corp, Boston Scientific Corp, Becton Dickinson and Co, SoundBite Medical Solutions, Medtronic Plc, Terumo Corp, Abbott, and Koninklijke Philips NV are among the key companies operating in the chronic total occlusion market.

US Census Bureau, World Health Organization (WHO), British Heart Foundation, French National Institute for Demographic Studies, National Institute of Statistics (NIS), National Library of Medicine, National Crime Records Bureau (NCRB), and National Center for Biotechnology Information are among the primary and secondary sources referred to while preparing the chronic total occlusion market report.

1. Introduction

1.1 Report Guidance
1.2 Market Segmentation

2. Executive Summary

2.1 Analyst Market Outlook

3. Research Methodology

3.1 Secondary Research
3.2 Primary Research
- 3.2.1 Hypothesis formulation:
- 3.2.2 Macro-economic factor analysis:
- 3.2.3 Developing base number:
- 3.2.4 Data Triangulation:
- 3.2.5 Country level data:
3.3 Assumptions and Limitations

4. Chronic Total Occlusion Market Landscape

4.1 Overview
4.2 North America PEST Analysis
4.3 Europe PEST Analysis
4.4 Asia Pacific PEST Analysis
4.5 Middle-East and Africa PEST Analysis
4.6 South and Central America PEST Analysis

5. Chronic Total Occlusion Market - Key Market Dynamics

5.1 Chronic Total Occlusion Market - Key Market Dynamics
5.2 Market Drivers
- 5.2.1 Increasing Aging Population
- 5.2.2 Rising Prevalence of Cardiovascular Diseases
5.3 Market Restraints
- 5.3.1 High Cost of Occlusion Devices
5.4 Market Opportunities
- 5.4.1 Strategic Initiatives by Market Players
5.5 Future Trends
- 5.5.1 Technological Advancements in CTO Devices
5.6 Impact of Drivers and Restraints:

6. Chronic Total Occlusion Market - Global Market Analysis

6.1 Chronic Total Occlusion Market Revenueand Forecast (US$ Million), 2021-2031
6.2 Chronic Total Occlusion Market Forecast and Analysis
6.3 Market Positioning of Key Players

7. Chronic Total Occlusion Market Volume and Revenue Analysis - by Equipment

7.1 Guide Wire
- 7.1.1 Overview
- 7.1.2 Guide Wire: Chronic Total Occlusion Market - Revenue and Forecast to 2031 (US$ Million)
7.2 Micro Catheters
- 7.2.1 Overview
- 7.2.2 Micro Catheters: Chronic Total Occlusion Market - Revenue and Forecast to 2031 (US$ Million)
7.3 Crossing Devices
- 7.3.1 Overview
- 7.3.2 Crossing Devices: Chronic Total Occlusion Market - Revenue and Forecast to 2031 (US$ Million)
7.4 Re-Entry Devices
- 7.4.1 Overview
- 7.4.2 Re-Entry Devices: Chronic Total Occlusion Market - Revenue and Forecast to 2031 (US$ Million)
7.5 Others
- 7.5.1 Overview
- 7.5.2 Others: Chronic Total Occlusion Market - Revenue and Forecast to 2031 (US$ Million)

8. Chronic Total Occlusion Market Revenue Analysis - by End User

8.1 Hospitals
- 8.1.1 Overview
- 8.1.2 Hospitals: Chronic Total Occlusion Market - Revenue and Forecast to 2031 (US$ Million)
8.2 Ambulatory Care Centers
- 8.2.1 Overview
- 8.2.2 Ambulatory Care Centers: Chronic Total Occlusion Market - Revenue and Forecast to 2031 (US$ Million)
8.3 Others
- 8.3.1 Overview
- 8.3.2 Others: Chronic Total Occlusion Market - Revenue and Forecast to 2031 (US$ Million)

9. Chronic Total Occlusion Market - Geographical Analysis

9.1 Overview
9.2 North America
- 9.2.1 North America Chronic Total Occlusion Market Overview
- 9.2.2 North America: Chronic Total Occlusion Market - Revenue and Forecast, 2021-2031 (US$Million)
  - 9.2.2.1 North America: Chronic Total Occlusion Market Volume and Forecast and Analysis - by Equipment
  - 9.2.2.2 North America: Chronic Total Occlusion Market - Revenue and Forecast and Analysis - by Equipment
  - 9.2.2.3 North America: Chronic Total Occlusion Market - Revenue and Forecast and Analysis - by End User
  - 9.2.2.4 United States: Chronic Total Occlusion Market - Revenue and Forecast to 2031 (US$ Million)
  - 9.2.2.5 Canada: Chronic Total Occlusion Market - Revenue and Forecast to 2031 (US$ Million)
  - 9.2.2.6 Mexico: Chronic Total Occlusion Market - Revenue and Forecast to 2031 (US$ Million)
9.3 Europe
- 9.3.1 Europe Chronic Total Occlusion Market Overview
- 9.3.2 Europe: Chronic Total Occlusion Market - Revenue and Forecast, 2021-2031 (US$Million)
  - 9.3.2.1 Europe: Chronic Total Occlusion Market Volume and Forecast and Analysis - by Equipment
  - 9.3.2.2 Europe: Chronic Total Occlusion Market - Revenue and Forecast and Analysis - by Equipment
  - 9.3.2.3 Europe: Chronic Total Occlusion Market - Revenue and Forecast and Analysis - by End User
- 9.3.3 Europe: Chronic Total Occlusion Market - Revenue and Forecast and Analysis - by Country
  - 9.3.3.1 Germany: Chronic Total Occlusion Market - Revenue and Forecast to 2031 (US$ Million)
    - 9.3.3.1.1 Germany: Chronic Total Occlusion Market Breakdown, by End User
  - 9.3.3.2 United Kingdom: Chronic Total Occlusion Market - Revenue and Forecast to 2031 (US$ Million)
    - 9.3.3.2.1 United Kingdom: Chronic Total Occlusion Market Breakdown, by Equipment
    - 9.3.3.2.2 United Kingdom: Chronic Total Occlusion Market Breakdown, by End User
  - 9.3.3.3 France: Chronic Total Occlusion Market - Revenue and Forecast to 2031 (US$ Million)
    - 9.3.3.3.1 France: Chronic Total Occlusion Market Breakdown, by Equipment
    - 9.3.3.3.2 France: Chronic Total Occlusion Market Breakdown, by End User
  - 9.3.3.4 Spain: Chronic Total Occlusion Market - Revenue and Forecast to 2031 (US$ Million)
    - 9.3.3.4.1 Spain: Chronic Total Occlusion Market Breakdown, by Equipment
    - 9.3.3.4.2 Spain: Chronic Total Occlusion Market Breakdown, by End User
  - 9.3.3.5 Italy: Chronic Total Occlusion Market - Revenue and Forecast to 2031 (US$ Million)
    - 9.3.3.5.1 Italy: Chronic Total Occlusion Market Breakdown, by Equipment
    - 9.3.3.5.2 Italy: Chronic Total Occlusion Market Breakdown, by End User
  - 9.3.3.6 Rest of Europe: Chronic Total Occlusion Market - Revenue and Forecast to 2031 (US$ Million)
    - 9.3.3.6.1 Rest of Europe: Chronic Total Occlusion Market Breakdown, by Equipment
    - 9.3.3.6.2 Rest of Europe: Chronic Total Occlusion Market Breakdown, by End User
9.4 Asia Pacific
- 9.4.1 Asia Pacific Chronic Total Occlusion Market Overview
- 9.4.2 Asia Pacific: Chronic Total Occlusion Market - Revenue and Forecast, 2021-2031 (US$Million)
  - 9.4.2.1 Asia Pacific: Chronic Total Occlusion Market Volume and Forecast and Analysis - by Equipment
  - 9.4.2.2 Asia Pacific: Chronic Total Occlusion Market - Revenue and Forecast and Analysis - by Equipment
  - 9.4.2.3 Asia Pacific: Chronic Total Occlusion Market - Revenue and Forecast and Analysis - by End User
- 9.4.3 Asia Pacific: Chronic Total Occlusion Market - Revenue and Forecast and Analysis - by Country
  - 9.4.3.1 China: Chronic Total Occlusion Market - Revenue and Forecast to 2031 (US$ Million)
    - 9.4.3.1.1 China: Chronic Total Occlusion Market Breakdown, by Equipment
    - 9.4.3.1.2 China: Chronic Total Occlusion Market Breakdown, by End User
  - 9.4.3.2 Japan: Chronic Total Occlusion Market - Revenue and Forecast to 2031 (US$ Million)
    - 9.4.3.2.1 Japan: Chronic Total Occlusion Market Breakdown, by Equipment
    - 9.4.3.2.2 Japan: Chronic Total Occlusion Market Breakdown, by End User
  - 9.4.3.3 India: Chronic Total Occlusion Market - Revenue and Forecast to 2031 (US$ Million)
    - 9.4.3.3.1 India: Chronic Total Occlusion Market Breakdown, by Equipment
    - 9.4.3.3.2 India: Chronic Total Occlusion Market Breakdown, by End User
  - 9.4.3.4 Australia: Chronic Total Occlusion Market - Revenue and Forecast to 2031 (US$ Million)
    - 9.4.3.4.1 Australia: Chronic Total Occlusion Market Breakdown, by Equipment
    - 9.4.3.4.2 Australia: Chronic Total Occlusion Market Breakdown, by End User
  - 9.4.3.5 South Korea: Chronic Total Occlusion Market - Revenue and Forecast to 2031 (US$ Million)
    - 9.4.3.5.1 South Korea: Chronic Total Occlusion Market Breakdown, by Equipment
    - 9.4.3.5.2 South Korea: Chronic Total Occlusion Market Breakdown, by End User
  - 9.4.3.6 Rest of APAC: Chronic Total Occlusion Market - Revenue and Forecast to 2031 (US$ Million)
    - 9.4.3.6.1 Rest of APAC: Chronic Total Occlusion Market Breakdown, by Equipment
    - 9.4.3.6.2 Rest of APAC: Chronic Total Occlusion Market Breakdown, by End User
9.5 Middle East and Africa
- 9.5.1 Middle East and Africa Chronic Total Occlusion Market Overview
- 9.5.2 Middle East and Africa: Chronic Total Occlusion Market - Revenue and Forecast, 2021-2031 (US$Million)
  - 9.5.2.1 Middle East and Africa: Chronic Total Occlusion Market Volume and Forecast and Analysis - by Equipment
  - 9.5.2.2 Middle East and Africa: Chronic Total Occlusion Market - Revenue and Forecast and Analysis - by Equipment
  - 9.5.2.3 Middle East and Africa: Chronic Total Occlusion Market - Revenue and Forecast and Analysis - by End User
- 9.5.3 Middle East and Africa: Chronic Total Occlusion Market - Revenue and Forecast and Analysis - by Country
  - 9.5.3.1 Middle East and Africa: Chronic Total Occlusion Market - Revenue and Forecast and Analysis - by Country
  - 9.5.3.2 Saudi Arabia: Chronic Total Occlusion Market - Revenue and Forecast to 2031 (US$ Million)
    - 9.5.3.2.1 Saudi Arabia: Chronic Total Occlusion Market Breakdown, by Equipment
    - 9.5.3.2.2 Saudi Arabia: Chronic Total Occlusion Market Breakdown, by End User
  - 9.5.3.3 South Africa: Chronic Total Occlusion Market - Revenue and Forecast to 2031 (US$ Million)
    - 9.5.3.3.1 South Africa: Chronic Total Occlusion Market Breakdown, by Equipment
    - 9.5.3.3.2 South Africa: Chronic Total Occlusion Market Breakdown, by End User
  - 9.5.3.4 United Arab Emirates: Chronic Total Occlusion Market - Revenue and Forecast to 2031 (US$ Million)
    - 9.5.3.4.1 United Arab Emirates: Chronic Total Occlusion Market Breakdown, by Equipment
    - 9.5.3.4.2 United Arab Emirates: Chronic Total Occlusion Market Breakdown, by End User
  - 9.5.3.5 Rest of Middle East and Africa: Chronic Total Occlusion Market - Revenue and Forecast to 2031 (US$ Million)
    - 9.5.3.5.1 Rest of Middle East and Africa: Chronic Total Occlusion Market Breakdown, by Equipment
    - 9.5.3.5.2 Rest of Middle East and Africa: Chronic Total Occlusion Market Breakdown, by End User
9.6 South and Central America
- 9.6.1 South and Central America Chronic Total Occlusion Market Overview
- 9.6.2 South and Central America: Chronic Total Occlusion Market - Revenue and Forecast, 2021-2031 (US$Million)
  - 9.6.2.1 South and Central America: Chronic Total Occlusion Market Volume and Forecast and Analysis - by Equipment
  - 9.6.2.2 South and Central America: Chronic Total Occlusion Market - Revenue and Forecast and Analysis - by Equipment
  - 9.6.2.3 South and Central America: Chronic Total Occlusion Market Volume and Forecast and Analysis - by End User
  - 9.6.2.4 South and Central America: Chronic Total Occlusion Market - Revenue and Forecast and Analysis - by End User
- 9.6.3 South and Central America: Chronic Total Occlusion Market - Revenue and Forecast and Analysis - by Country
  - 9.6.3.1 Brazil: Chronic Total Occlusion Market - Revenue and Forecast to 2031 (US$ Million)
    - 9.6.3.1.1 Brazil: Chronic Total Occlusion Market Breakdown, by Equipment
    - 9.6.3.1.2 Brazil: Chronic Total Occlusion Market Breakdown, by End User
  - 9.6.3.2 Argentina: Chronic Total Occlusion Market - Revenue and Forecast to 2031 (US$ Million)
    - 9.6.3.2.1 Argentina: Chronic Total Occlusion Market Breakdown, by Equipment
    - 9.6.3.2.2 Argentina: Chronic Total Occlusion Market Breakdown, by End User
  - 9.6.3.3 Rest of South and Central America: Chronic Total Occlusion Market - Revenue and Forecast to 2031 (US$ Million)
    - 9.6.3.3.1 Rest of South and Central America: Chronic Total Occlusion Market Breakdown, by Equipment
    - 9.6.3.3.2 Rest of South and Central America: Chronic Total Occlusion Market Breakdown, by End User

10. Impact of COVID-19 Pandemic on Global Chronic Total Occlusion Market

10.1 North America
10.2 Europe
10.3 Asia-Pacific
10.4 Middle East and Africa
10.5 South and Central America

11. Chronic Total Occlusion Market - Industry Landscape

11.1 Overview
11.2 Growth Strategies in the Chronic Total Occlusion Market
11.3 Organic Growth Strategies
- 11.3.1 Overview
11.4 Inorganic Growth Strategies
- 11.4.1 Overview

12. Company Profiles

12.1 Asahi Intecc Co Ltd
- 12.1.1 Key Facts
- 12.1.2 Business Description
- 12.1.3 Products and Services
- 12.1.4 Financial Overview
- 12.1.5 SWOT Analysis
- 12.1.6 Key Developments
12.2 Cordis Corp
- 12.2.1 Key Facts
- 12.2.2 Business Description
- 12.2.3 Products and Services
- 12.2.4 Financial Overview
- 12.2.5 SWOT Analysis
- 12.2.6 Key Developments
12.3 Integer Holdings Corp
- 12.3.1 Key Facts
- 12.3.2 Business Description
- 12.3.3 Products and Services
- 12.3.4 Financial Overview
- 12.3.5 SWOT Analysis
- 12.3.6 Key Developments
12.4 Boston Scientific Corp
- 12.4.1 Key Facts
- 12.4.2 Business Description
- 12.4.3 Products and Services
- 12.4.4 Financial Overview
- 12.4.5 SWOT Analysis
- 12.4.6 Key Developments
12.5 Koninklijke Philips NV
- 12.5.1 Key Facts
- 12.5.2 Business Description
- 12.5.3 Products and Services
- 12.5.4 Financial Overview
- 12.5.5 SWOT Analysis
- 12.5.6 Key Developments
12.6 Becton Dickinson and Co
- 12.6.1 Key Facts
- 12.6.2 Business Description
- 12.6.3 Products and Services
- 12.6.4 Financial Overview
- 12.6.5 SWOT Analysis
- 12.6.6 Key Developments
12.7 Sound Bite Medical Solutions
- 12.7.1 Key Facts
- 12.7.2 Business Description
- 12.7.3 Products and Services
- 12.7.4 Financial Overview
- 12.7.5 SWOT Analysis
- 12.7.6 Key Developments
12.8 Medtronic Plc
- 12.8.1 Key Facts
- 12.8.2 Business Description
- 12.8.3 Products and Services
- 12.8.4 Financial Overview
- 12.8.5 SWOT Analysis
- 12.8.6 Key Developments
12.9 Terumo Corp
- 12.9.1 Key Facts
- 12.9.2 Business Description
- 12.9.3 Products and Services
- 12.9.4 Financial Overview
- 12.9.5 SWOT Analysis
- 12.9.6 Key Developments
12.10 Abbott Laboratories
- 12.10.1 Key Facts
- 12.10.2 Business Description
- 12.10.3 Products and Services
- 12.10.4 Financial Overview
- 12.10.5 SWOT Analysis
- 12.10.6 Key Developments

13. Appendix

13.1 About The Insight Partners
13.2 Glossary of Terms